Delveinsight

AUGUST 27, 2020

Moderna’s COVID-19 vaccine triggers an immune response in older adults. As observed in 45 younger adults, the middle dose of the vaccine triggered the production of neutralizing antibodies against SARS-CoV-2, the virus, which causes COVID-19 , in 10 patients aged 56 to 70 and 10 patients over 71.

Vaccine 53

Vaccine Vaccination Research Trials 53

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Antibody 40

Antibody Vaccine Vaccination Trials 40

The Pharma Data

DECEMBER 10, 2020

The vaccine targeted both the inner nucleocapsid (N) and the outer spike (S) proteins of the virus to maximize the immune response. The goal of targeting both S and N was to both activate virus-specific T cells and generate anti-SARS-CoV-2-neutralizing antibodies. This press release features multimedia. Graphic: Business Wire).

Vaccine 52

Vaccine Vaccination Immune Response Protein 52

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. The team obtained sequences from the newly circulating B.1.1.7 1.351 Beta, P1 Gamma, and B.1.617.2

Vaccine 52

Vaccine Vaccination Research Immune Response 52

The Pharma Data

MARCH 26, 2021

The study enrolled 572 people, of whom 554 were in the intention-to-treat WT population, which excluded people with EGFR or ALK genomic tumour aberrations, and were randomised 1:1 to receive: Tecentriq monotherapy, until disease progression (or loss of clinical benefit, as assessed by the investigator), unacceptable toxicity or death; or.

HR 52

HR Protein Genome Genomics 52

The Pharma Data

MARCH 16, 2021

1 lineage gained prominence in late 2020, with each carrying a number of genomic mutations. 1.351 carries another spike mutation E484K, which appears to evade the body’s immune response, possibly diminishing vaccine efficacy. Variants of B.1.1.7, 1.351 and P.1 2,3 Another variant, B.1.351, 4 Variant P.1,

Antibody 52

Antibody Clinical Trials Clinical Trials Vaccination 52

The Pharma Data

OCTOBER 14, 2020

Potential Development of Human Monoclonal Antibody Therapeutics to SARS-CoV-2. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. CHATHAM, N.J., Ilya Trakht, Ph.D.,

Vaccine 40

Vaccine Vaccination Development Medicine 40

The Pharma Data

MAY 4, 2021

The study enrolled 572 people, of whom 554 were in the intention-to-treat WT population, which excluded people with EGFR or ALK genomic tumour aberrations, and were randomised 1:1 to receive: Tecentriq monotherapy, until disease progression (or loss of clinical benefit, as assessed by the investigator), unacceptable toxicity or death; or.

Protein 52

Protein HR In-Vitro Medicine 52

XTalks

DECEMBER 17, 2021

Initial lab studies, including one from South Africa, show that vaccine-induced antibodies may be less effective at neutralizing Omicron. The company recently released data from an early-stage trial evaluating the vaccine, which showed that it has a good safety profile and elicits immune responses against four strains of influenza.

Life Science 98

Life Science Vaccine Vaccination Trials 98

Pharma Marketing Network

JANUARY 20, 2021

It’s widely acknowledged that optimal vaccine immunity results from engaging both humoral and cellular responses, but less attention has been given to the role of mucosal immunity in protecting against COVID-19, which is surprising considering SARS-CoV-2 enters the human body primarily through the mucosal surfaces of the upper respiratory tract.

Vaccine 52

Vaccine Vaccination In-Vivo Genetics 52

Roots Analysis

OCTOBER 30, 2023

Self-amplifying RNA (saRNA): Self amplifying RNA is an engineered form of RNA, combining the amplifying genome (native to certain viruses) to the therapeutic gene of interest. This allows generation of multiple copies of the gene of interest at the target owing to the amplification property of the template.

RNA 40

RNA Vaccine Vaccination Development 40

The Pharma Data

JULY 23, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Hormones 52

Hormones Trials Genome Genomics 52

The Pharma Data

MARCH 11, 2021

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Genome Genomics 52

Pfizer

NOVEMBER 2, 2022

The influenza virus is subject to constant mutations to evade the host immune response, causing a seasonal variation in circulating strains. This is reminiscent of influenza, another respiratory disease that requires repeated vaccinations due to its genomic instability resulting in modifications of the surface protein hemagglutinin.

Vaccine 85

Vaccine Vaccination Clinical Trials Clinical Trials 85

The Pharma Data

AUGUST 11, 2020

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

Opdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor that is designed to uniquely harness the body’s own immune system to help restore anti-tumor immune response. By harnessing the body’s own immune system to fight cancer, Opdivo has become an important treatment option across multiple cancers.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

JANUARY 4, 2021

Food and Drug Administration (FDA) , in combination with Tecentriq ® (atezolizumab) for the first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression with no EGFR or ALK genomic tumor aberrations. TIGIT and PD-L1 are proteins that play a role in suppression of the immune system.

Medicine 52

Medicine Immune Response Protein Gene 52

XTalks

NOVEMBER 20, 2020

A new type of test based on detection of activated T cells may prove to have greater utility in determining whether someone has had a COVID-19 infection compared to a traditional antibody test. The cell-based tests are designed to identify specific T cells that are activated in response to a pathogen — which in this case would be SARS-CoV-2.

Antibody 98

Antibody Immune Response Protein In-Vitro 98